DiYES International School – New Pneumococcal Vaccine has been introduced on the National Immunisation Program in Australia to provide stronger protection for children across the country. This latest development replaces the older pneumococcal vaccines with an advanced version that covers more strains of the bacteria responsible for serious illnesses. Health experts believe this change will help reduce the number of infections such as meningitis, pneumonia, and ear infections in infants and young children. With its broader coverage and improved immune response, the vaccine aims to protect vulnerable groups including young children, older adults, and those with weakened immune systems. The arrival of this new vaccine marks a significant step in Australia’s ongoing effort to prevent life threatening pneumococcal disease and protect public health.
The New Pneumococcal Vaccine targets Streptococcus pneumoniae, a bacterium that causes a wide range of infections. Pneumococcal disease can lead to invasive conditions such as meningitis, a dangerous inflammation of the brain lining, and bacteraemia, a severe bloodstream infection. These illnesses can be life threatening, particularly in children, the elderly, and people with chronic illnesses. Pneumococcus is also a leading cause of bacterial pneumonia and middle ear infections that often result in hospitalisation. There are more than 100 strains of this bacterium, but only some frequently cause disease in humans. Healthy individuals, especially young children, may carry the bacteria in the back of the nose without showing symptoms. Transmission typically occurs through respiratory droplets, making close contact a key factor in the spread.
“Read about: Tragedy in Gaza: 404 Dead from Hunger, 141 Innocent Children Among Victims!”
The fight against pneumococcal disease has evolved over the past century with the development of more advanced vaccines. Early pneumococcal vaccines relied on polysaccharides from the bacterial capsule to create immunity. While these vaccines offered protection against many strains, their effect tended to be short lived. Pneumococcal conjugate vaccines or PCVs were later developed to improve immune response and provide longer lasting protection. These vaccines link the polysaccharide to a carrier protein, stimulating stronger immunity. Australia first introduced a seven strain PCV in 2005 before upgrading to a 13 strain version in 2011. Real world data demonstrated that these vaccines were around 90 percent effective in preventing invasive disease caused by the targeted strains. However, as pneumococcus continued to evolve, new versions became necessary to keep pace with emerging strains.
The latest upgrade in Australia’s immunisation program is the 20 strain PCV, known as 20vPCV. This vaccine includes all 13 strains from the previous version plus seven additional strains to provide broader protection. Clinical trials confirmed that 20vPCV produces strong immune responses against all 20 strains, including those shared with the 13 strain vaccine. Experts expect the new formulation to prevent up to 30 percent more cases of invasive pneumococcal disease compared to the older vaccine. It is also expected to reduce less severe infections such as pneumonia and ear infections. The hidden advantage of this vaccine lies in its ability to reduce bacterial colonisation in the nose, which lowers transmission and protects the wider community. This indirect benefit is expected to decrease infections even in unvaccinated children and adults.
Health authorities recommend three doses of 20vPCV for infants at two four and twelve months of age. An additional dose at six months protects Aboriginal and Torres Strait Islander children and those with high medical risk. Children starting vaccination with the older 13 strain version can complete the series with the new vaccine without extra doses. Clinical trials confirm that 20vPCV shows a safety profile similar to the previous vaccine used for more than fifteen years. New recommendations replace 13vPCV and remove the need for the older 23 strain polysaccharide vaccine for children. The simplified schedule improves vaccination rates and strengthens protection for infants and communities across Australia.
The rollout of the New Pneumococcal Vaccine is expected to bring significant public health benefits for Australia. By preventing more cases of serious pneumococcal disease, the vaccine will reduce hospitalisations, medical costs, and the burden on families. Data from previous vaccine programs show that high coverage not only protects vaccinated individuals but also creates herd immunity that shields the wider community. With over 90 percent of Australian children already receiving pneumococcal vaccines, health officials are optimistic that the new program will achieve even higher compliance. The World Health Organization continues to recommend pneumococcal conjugate vaccines as a core part of childhood immunisation programs worldwide. Australia’s adoption of the 20 strain vaccine sets a strong example of proactive disease prevention and ongoing commitment to child health.
This article is sourced from theconversation.com and for more details you can read at diyesinternational.com
Writer: Sarah Azhari
Editor: Anisa
